Drug Trial Radar · NCT00444522
Staccato Alprazolam Single Dose PK
Last checked: Nov 20, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Jun 2005
Primary completion
Aug 2005
Study completion Aug 2005
Sponsor
- Lead sponsor
- Alexza Pharmaceuticals, Inc.Not stated
- Sponsor type
- Not stated
- First posted
- Mar 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.
Conditions
- Healthy
Interventions
Alprazolam thermal aerosolDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic profile and dose proportionality
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.